You searched for Antibody candidate - Page 34 of 69

News and Trends 7 Dec 2016

Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies

…technologies to treat cancer. Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat non-Hodgkin lymphoma (NHL) and recently entered the trending antibody-drug conjugate (ADC) field to fight against leukemia. These promising…

December 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

antibody drug conjugate adc small cancer treatment

News and Trends 12 Jul 2022

Legochem Bioscience signs agreement with Glycotope to develop cancer drug

…GmbH will develop an antibody drug conjugate (ADC) by combining LBC’s technology with one of Glycotope’s investigational tumor targeting antibodies. ADCs are a class of biopharmaceutical drugs designed as a…

July 12, 2022 - 3 minutesmins - By Liza Laws

Interview 23 Oct 2019

Channeling the Power of AI into Personalizing Medicine

…established biotech Cambridge Antibody Technology. “I wanted to make a difference to patients’ lives — this was something that really interested me about human biology. That’s why I did biochemistry…

October 23, 2019 - 7 minutesmins - By Helen Albert

News and Trends 21 Nov 2017

German Biotech Reels in €34M for its Cancer-Killing Technology

Heidelberg Pharma is developing Antibody Targeted Amanitin Conjugates (ATACs), which combine antibody-drug conjugate technology with the toxin, Amanitin. Heidelberg Pharma has attracted over €34M of investment to support the development…

November 21, 2017 - 1 minutemin - By Alex Dale

News and Trends 15 Feb 2022

Next-Gen Covid-19 Vaccines and Drugs Crowd into Late-Stage Trials

…its Covid-19 vaccine candidate in June 2021, the German mRNA specialist CureVac pivoted to another candidate. The second-generation mRNA vaccine is being developed in partnership with GSK and showed promise…

February 15, 2022 - 7 minutesmins - By Jonathan Smith

Best in Biotech 2 Apr 2024

Chicago biotech: Seven players advancing the industry

…financing round, to advance its oncology therapeutic candidate and develop its nanotechnology platform further. This funding will support the progression of their first oncology candidate, the selection of a second…

April 2, 2024 - 8 minutesmins - By Jules Adam

News and Trends 13 Dec 2017

Biotech and Pharma Giants Make a Good Start to Phase II Trial for Skin Cancer

Regeneron and Sanofi have announced positive early results from a Phase II study investigating their skin cancer antibody, cemiplimab. Despite deciding to end their antibody partnership at the end of…

December 13, 2017 - 3 minutesmins - By Alex Dale

novo nordisk staten fat hypertriglyceridemia cardiovascular disease

News and Trends 17 Dec 2018

Novo Nordisk Partners Dutch Biotech to Prevent Cardiovascular Disease

…with high triglycerides and higher cardiovascular risk. Staten’s lead candidate, licensed from Belgian biotech argenx, is a human antibody that targets ApoC3, reducing fatty molecules in the blood. Though the…

December 17, 2018 - 2 minutesmins - By Jonathan Smith

Best in Biotech 11 Jul 2024

From data to discovery: Five bioinformatics companies you should know in 2024

…neuron disease that affects the nerve cells in the spinal cord and brain. The drug candidate VRG50635 is a small molecule PIKfyve inhibitor that was entirely discovered and developed using…

July 11, 2024 - 7 minutesmins - By Roohi Mariam Peter

Startup Scout 21 Nov 2022

Osivax is designing future-proof influenza and Covid vaccines

…T cells must often be tested in tissue samples. “If you can get an antibody-based vaccine that protects well and neutralizes the virus, you wouldn’t need to care that much…

November 21, 2022 - 5 minutesmins - By Jonathan Smith

In Depth 27 Mar 2024

Are new treatments for multiple sclerosis on the horizon?

…for different forms of multiple sclerosis. Vidofludimus calcium: a potential treatment for multiple sclerosis Mechanism of action of vidofludimus calcium Immunic Therapeutics’ vidofludimus calcium is a drug candidate being tested…

March 27, 2024 - 10 minutesmins - By Roohi Mariam Peter

News and Trends 20 Mar 2017

French Biotech fails Second Phase II Trial for Cardiovascular Disease

Cerenis therapeutic’s lead candidate CER-001 has failed Phase II for the treatment of patients with post-acute coronary syndrome (ACS). The French-based Biotech Cerenis is developing therapies for the treatment of…

March 20, 2017 - 3 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Antibody candidate

Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies

Legochem Bioscience signs agreement with Glycotope to develop cancer drug

Channeling the Power of AI into Personalizing Medicine

German Biotech Reels in €34M for its Cancer-Killing Technology

Next-Gen Covid-19 Vaccines and Drugs Crowd into Late-Stage Trials

Chicago biotech: Seven players advancing the industry

Biotech and Pharma Giants Make a Good Start to Phase II Trial for Skin Cancer

Novo Nordisk Partners Dutch Biotech to Prevent Cardiovascular Disease

From data to discovery: Five bioinformatics companies you should know in 2024

Osivax is designing future-proof influenza and Covid vaccines

Are new treatments for multiple sclerosis on the horizon?

French Biotech fails Second Phase II Trial for Cardiovascular Disease

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!